The study analyzed how well researchers reported adverse effects in 187 psoriasis randomized controlled trials published between 2020 and 2025. On average, they scored 6.00 points on the completeness of reporting scale, indicating suboptimal quality – only 26.2% of studies were rated as high quality. The occurrence of individual information varied widely, with the lowest reported data on adverse event management (16.0%), time of occurrence (20.3%), outcome (26.7%), and use of standardized coding systems (31.6%). The study found that articles published in journals with a higher impact factor and those focused on pustular psoriasis had better reporting of adverse events. The authors recommend that future studies strictly follow the CONSORT-Harms 2022 international standards so that patients receive balanced information about the benefits and harms of psoriasis treatment.